VRTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.20%

Insider Buying (Last 12 Months): $1,948,400.00

Insider Selling (Last 12 Months): $120,441,655.39

Vertex Pharmaceuticals Insider Trading History Chart

Vertex Pharmaceuticals Share Price & Price History

^$470.72

▼ -6.38 (-1.34%)

As of 08/3/2026 04:00 PM ET

Days: 30 | 90 | 365

Vertex Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/2/2026	Duncan McKechnie	EVP	Sell	1,541	$519.00	$799,779.00	11,001
7/2/2026	Ourania Tatsis	EVP	Sell	1,500	$524.99	$787,485.00	45,321
6/26/2026	Carmen Bozic	CMO	Sell	596	$482.50	$287,570.00	15,337
6/18/2026	Carmen Bozic	CMO	Sell	1,020	$462.17	$471,413.40	15,933
6/15/2026	Carmen Bozic	CMO	Sell	4,062	$450.00	$1,827,900.00	16,953
6/5/2026	Carmen Bozic	CMO	Sell	1,745	$450.00	$785,250.00	21,015
5/12/2026	Carmen Bozic	CMO	Sell	6,988	$450.00	$3,144,600.00	26,088
5/4/2026	Sangeeta N Bhatia	Director	Sell	318	$423.73	$134,746.14	4,924
5/1/2026	Joy Liu	EVP	Sell	1,104	$425.02	$469,222.08	20,729
4/1/2026	Joy Liu	EVP	Sell	978	$449.17	$439,288.26	21,833
3/13/2026	Carmen Bozic	CMO	Sell	2,329	$481.79	$1,122,088.91	35,405
2/25/2026	Amit Sachdev	EVP	Sell	1,846	$486.35	$897,802.10	55,570
2/25/2026	Duncan McKechnie	EVP	Sell	4,910	$487.65	$2,394,361.50	17,559
2/25/2026	E. Morrey Atkinson, III	EVP	Sell	668	$486.35	$324,881.80	18,432
2/25/2026	Jonathan Biller	EVP	Sell	945	$486.35	$459,600.75	13,659
2/25/2026	Kristen Ambrose	CAO	Sell	223	$486.35	$108,456.05	6,981
2/25/2026	Mark E. Bunnage	EVP	Sell	620	$486.35	$301,537.00	7,284
2/25/2026	Ourania Tatsis	EVP	Sell	260	$486.35	$126,451.00	46,763
2/19/2026	Amit Sachdev	EVP	Sell	58,613	$468.83	$27,479,532.79	58,934
2/13/2026	Ourania Tatsis	EVP	Sell	1,500	$499.99	$749,985.00	46,132
2/11/2026	E. Morrey Atkinson, III	EVP	Sell	1,751	$460.43	$806,212.93	22,046
2/11/2026	Jonathan Biller	EVP	Sell	1,925	$460.43	$886,327.75	20,819
2/11/2026	Kristen Ambrose	CAO	Sell	1,376	$460.43	$633,551.68	10,127
2/11/2026	Mark E. Bunnage	EVP	Sell	2,021	$460.43	$930,529.03	12,914
2/11/2026	Ourania Tatsis	EVP	Sell	466	$460.43	$214,560.38	51,436
1/7/2026	Ourania Tatsis	EVP	Sell	4,500	$474.99	$2,137,455.00	42,293
1/6/2026	Charles F. Wagner, Jr.	EVP	Sell	9,532	$461.00	$4,394,252.00	37,725
12/3/2025	Charles F. Wagner, Jr.	EVP	Sell	14,000	$456.00	$6,384,000.00	37,725
12/3/2025	Jeffrey M. Leiden	Chairman	Sell	63,781	$449.20	$28,650,425.20	24,026
11/14/2025	Jeffrey M. Leiden	Chairman	Sell	53,604	$440.72	$23,624,354.88	24,026
11/13/2025	Jeffrey M. Leiden	Chairman	Sell	19,688	$440.27	$8,668,035.76	24,026
8/6/2025	Bruce I. Sachs	Director	Buy	5,000	$389.68	$1,948,400.00	45,000
5/15/2025	David Altshuler	EVP	Sell	52	$424.69	$22,083.88	23,281
3/10/2025	David Altshuler	EVP	Sell	3,231	$500.00	$1,615,500.00	26,512
2/27/2025	Ourania Tatsis	EVP	Sell	530	$475.34	$251,930.20	58,539
2/18/2025	Ourania Tatsis	EVP	Sell	244	$455.06	$111,034.64	67,695
2/11/2025	Ourania Tatsis	EVP	Sell	310	$459.83	$142,547.30	64,021
11/15/2024	David Altshuler	EVP	Sell	15	$478.56	$7,178.40	25,813
8/30/2024	Jeffrey M. Leiden	Chairman	Sell	3,784	$499.00	$1,888,216.00	9,994
8/30/2024	Sangeeta N Bhatia	Director	Sell	646	$500.00	$323,000.00	4,435
8/7/2024	Carmen Bozic	CMO	Sell	2,280	$476.75	$1,086,990.00	23,259
8/1/2024	Bruce I. Sachs	Director	Sell	5,295	$508.00	$2,689,860.00	40,000
7/24/2024	Carmen Bozic	CMO	Sell	2,280	$488.46	$1,113,688.80	25,539
7/22/2024	Reshma Kewalramani	CEO	Sell	15,202	$497.00	$7,555,394.00	106,172
7/10/2024	Carmen Bozic	CMO	Sell	2,280	$487.34	$1,111,135.20	27,819
6/26/2024	Carmen Bozic	CMO	Sell	2,280	$471.72	$1,075,521.60	30,099
6/12/2024	Carmen Bozic	CMO	Sell	2,280	$478.00	$1,089,840.00	32,379
6/12/2024	E. Morrey Atkinson, III	EVP	Sell	7,288	$478.00	$3,483,664.00	15,972
5/30/2024	Ourania Tatsis	EVP	Sell	2,350	$439.11	$1,031,908.50	53,523
5/29/2024	Carmen Bozic	CMO	Sell	2,280	$445.56	$1,015,876.80	34,659
5/28/2024	Charles F. Wagner, Jr.	CFO	Sell	3,250	$454.79	$1,478,067.50	50,387
5/24/2024	Reshma Kewalramani	CEO	Sell	1,565	$457.00	$715,205.00	121,374
5/22/2024	Bruce I. Sachs	Director	Sell	7,073	$448.00	$3,168,704.00	40,000
2/26/2024	Ourania Tatsis	EVP	Sell	354	$425.70	$150,697.80	55,804
2/20/2024	Ourania Tatsis	EVP	Sell	480	$420.79	$201,979.20	59,827
2/12/2024	Amit Sachdev	EVP	Sell	3,222	$420.24	$1,354,013.28	74,364
2/12/2024	Jeffrey M. Leiden	Chairman	Sell	2,656	$419.51	$1,114,218.56	27,644
2/12/2024	Kristen Ambrose	CAO	Sell	1,374	$420.24	$577,409.76	9,676
2/12/2024	Stuart A. Arbuckle	COO	Sell	4,295	$420.24	$1,804,930.80	75,718
1/8/2024	Jeffrey M. Leiden	Chairman	Sell	6,648	$419.07	$2,785,977.36	2,423
11/6/2023	Bruce I. Sachs	Director	Sell	11,250	$385.00	$4,331,250.00	40,000
10/31/2023	Carmen Bozic	CMO	Sell	5,651	$355.92	$2,011,303.92	34,952
10/17/2023	Carmen Bozic	CMO	Sell	5,651	$373.25	$2,109,235.75	40,603
10/17/2023	Sangeeta N Bhatia	Director	Sell	243	$375.00	$91,125.00	3,901
10/16/2023	Jeffrey M. Leiden	Chairman	Sell	12,962	$374.00	$4,847,788.00	22,425
10/6/2023	Sangeeta N Bhatia	Director	Sell	242	$360.00	$87,120.00	4,144
10/3/2023	Carmen Bozic	CMO	Sell	5,651	$345.28	$1,951,177.28	46,254
10/2/2023	Jonathan Biller	EVP	Sell	610	$346.76	$211,523.60	10,569
9/19/2023	Carmen Bozic	CMO	Sell	5,651	$351.00	$1,983,501.00	51,905
8/23/2023	Ourania Tatsis	EVP	Sell	2,500	$355.00	$887,500.00	48,637
8/9/2023	David Altshuler	EVP	Sell	63	$345.51	$21,767.13	32,038
8/9/2023	Sangeeta N Bhatia	Director	Sell	242	$345.51	$83,613.42	4,386

SEC Filings (Institutional Ownership Changes) for Vertex Pharmaceuticals (NASDAQ:VRTX)

90.96% of Vertex Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Vertex Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
7/14/2026	Trust Asset Management LLC	2,827	$1.40M	0.0%	-1.0%	0.001%
7/10/2026	Regent Peak Wealth Advisors LLC	637	$0.32M	0.1%	+8.3%	0.000%
7/10/2026	Abound Wealth Management	50	$25K	0.0%	-34.2%	0.000%
7/10/2026	Tema ETFs LLC	9,060	$4.50M	0.1%	-6.0%	0.004%
7/10/2026	William Mack & Associates Inc.	630	$0.31M	0.1%	-5.8%	0.000%
7/10/2026	Generali Investments Management Co LLC	4,926	$2.45M	0.5%	+46.3%	0.002%
7/10/2026	Handelsbanken Fonder AB	218,292	$108.43M	0.3%	-1.2%	0.086%
7/10/2026	City Holding Co.	73	$36K	0.0%	+128.1%	0.000%
7/10/2026	Redhawk Wealth Advisors Inc.	1,190	$0.59M	0.1%	+2.2%	0.000%
7/10/2026	LVM Capital Management Ltd. MI	24,986	$12.41M	1.0%	-3.3%	0.010%
7/10/2026	Community Financial Services Group LLC	53	$26K	0.0%	N/A	0.000%
7/10/2026	Perkins Coie Trust Co	95	$47K	0.0%	N/A	0.000%
7/10/2026	Hoffman Alan N Investment Management	440	$0.22M	0.1%	N/A	0.000%
7/10/2026	Fulton Bank N.A.	987	$0.49M	0.0%	+9.1%	0.000%
7/10/2026	Wealthcare Advisory Partners LLC	4,627	$2.30M	0.0%	-4.4%	0.002%
7/9/2026	Harrell Investment Partners LLC	4,415	$2.19M	0.5%	+1.5%	0.002%
7/9/2026	Sapient Capital LLC	18,011	$8.95M	0.1%	-5.2%	0.007%
7/9/2026	Wealth Science Advisors LLC	2,730	$1.36M	0.6%	+34.1%	0.001%
7/9/2026	Everhart Financial Group Inc.	2,566	$1.28M	0.1%	+4.5%	0.001%
7/9/2026	Everpar Advisors LLC	986	$0.49M	0.1%	+7.3%	0.000%
7/9/2026	Hennion & Walsh Asset Management Inc.	3,983	$1.98M	0.1%	-1.1%	0.002%
7/9/2026	Breakwater Capital Group	1,992	$0.99M	0.1%	+1.5%	0.001%
7/9/2026	Valeo Financial Advisors LLC	3,787	$1.88M	0.0%	+8.2%	0.001%
7/8/2026	Atwood & Palmer Inc.	56,357	$27.99M	1.5%	+1.1%	0.022%
7/8/2026	Beacon Investment Advisory Services Inc.	53,380	$26.52M	1.0%	-4.9%	0.021%
7/8/2026	Chesley Taft & Associates LLC	1,082	$0.54M	0.0%	+24.5%	0.000%
7/8/2026	Trust Point Inc.	793	$0.39M	0.0%	+2.7%	0.000%
7/8/2026	FNY Investment Advisers LLC	100	$49K	0.0%	N/A	0.000%
7/8/2026	Cooper Financial Group	5,261	$2.61M	0.2%	+14.4%	0.002%
7/8/2026	Elevation Wealth Partners LLC	55	$27K	0.0%	+103.7%	0.000%
7/8/2026	Czech National Bank	72,243	$35.89M	0.2%	+4.4%	0.028%
7/8/2026	PensionDanmark Pensionsforsikringsaktieselskab	54,094	$26.87M	0.2%	+9.9%	0.021%
7/8/2026	Assenagon Asset Management S.A.	759,564	$377.30M	0.5%	+41.4%	0.299%
7/8/2026	Apella Capital LLC	603	$0.32M	0.0%	N/A	0.000%
7/7/2026	180 Wealth Advisors LLC	548	$0.27M	0.0%	-4.7%	0.000%
7/7/2026	Foster Group Inc.	575	$0.29M	0.0%	+16.4%	0.000%
7/7/2026	Trust Asset Management LLC	2,827	$1.40M	0.1%	-1.0%	0.001%
7/7/2026	Balefire LLC	479	$0.24M	0.0%	-37.3%	0.000%
7/7/2026	Dynamic Advisor Solutions LLC	2,984	$1.48M	0.0%	-15.9%	0.001%
7/7/2026	GK Wealth Management LLC	922	$0.46M	0.2%	N/A	0.000%
7/7/2026	BDF Gestion	4,370	$2.17M	0.3%	-10.1%	0.002%
7/7/2026	GAMMA Investing LLC	6,918	$3.44M	0.1%	+4.9%	0.003%
7/7/2026	Central Pacific Bank Trust Division	5,123	$2.55M	0.3%	+1.9%	0.002%
7/7/2026	Canandaigua National Bank & Trust Co.	427	$0.21M	0.0%	N/A	0.000%
7/7/2026	Moody National Bank Trust Division	2,484	$1.23M	0.1%	-1.3%	0.001%
7/7/2026	Grove Bank & Trust	2,525	$1.25M	0.1%	-4.6%	0.001%
7/7/2026	CoreCap Advisors LLC	442	$0.22M	0.0%	-14.0%	0.000%
7/6/2026	Bangor Savings Bank	4,470	$2.22M	0.2%	+0.4%	0.002%
7/6/2026	Stonebridge Financial Group LLC	433	$0.22M	0.0%	N/A	0.000%
7/6/2026	RDA Financial Network	8,419	$4.18M	0.9%	+17.2%	0.003%
7/6/2026	Dogwood Wealth Management LLC	50	$25K	0.0%	-30.6%	0.000%
7/2/2026	MassMutual Private Wealth & Trust FSB	28,385	$14.10M	0.4%	-1.2%	0.011%
7/2/2026	Hilltop National Bank	303	$0.15M	0.0%	+11.4%	0.000%
7/2/2026	CX Institutional	1,838	$0.91M	0.0%	-5.3%	0.001%
7/1/2026	Eastern Bank	305	$0.15M	0.0%	-15.7%	0.000%
7/1/2026	Trust Co of the South	834	$0.41M	0.1%	-10.7%	0.000%
6/22/2026	Sapient Capital LLC	18,992	$8.48M	0.1%	-44.7%	0.007%
6/18/2026	Western Wealth Management LLC	1,631	$0.73M	0.0%	+159.7%	0.001%
6/18/2026	Pacer Advisors Inc.	88,863	$39.68M	0.1%	+16.7%	0.035%
6/15/2026	Carmignac Gestion	148,199	$66.16M	1.0%	-22.6%	0.058%
6/9/2026	Rathbones Group PLC	955	$0.43M	0.0%	-23.2%	0.000%
6/8/2026	First National Bank of Mount Dora Trust Investment Services	7,211	$3.22M	0.7%	+16.1%	0.003%
6/3/2026	Parallel Advisors LLC	5,522	$2.47M	0.0%	+6.4%	0.002%
6/3/2026	NewEdge Advisors LLC	17,146	$7.66M	0.0%	-1.1%	0.007%
6/1/2026	Keel Point LLC	947	$0.42M	0.0%	-22.1%	0.000%
5/29/2026	Ramiah Investment Group	969	$0.43M	0.4%	-7.2%	0.000%
5/29/2026	Asset Dedication LLC	237	$0.11M	0.0%	-19.4%	0.000%
5/27/2026	Alpine Woods Capital Investors LLC	716	$0.32M	0.1%	-48.9%	0.000%
5/26/2026	Glenmede Trust Co. NA	5,608	$2.50M	0.0%	+5.0%	0.002%
5/26/2026	Axiom Investment Management LLC	633	$0.28M	0.2%	N/A	0.000%
5/22/2026	Groupama Asset Managment	165,897	$74.08M	1.1%	+1.7%	0.065%
5/22/2026	Segall Bryant & Hamill LLC	38,073	$17M	0.2%	-4.4%	0.015%
5/21/2026	Montchanin Asset Management LLC	6,932	$3.10M	3.1%	N/A	0.003%
5/21/2026	GKV Capital Management Co. Inc.	4,417	$1.97M	0.7%	+2.6%	0.002%
5/21/2026	Vestor Capital LLC	202	$90K	0.0%	+38.4%	0.000%
5/21/2026	BankChampaign National Association	1,374	$0.61M	0.6%	N/A	0.001%
5/20/2026	CCM Investment Advisers LLC	25,894	$11.56M	1.1%	-1.4%	0.010%
5/20/2026	Liontrust Investment Partners LLP	13,691	$6.11M	0.1%	-9.0%	0.005%
5/19/2026	Western Wealth Management LLC	1,631	$0.73M	0.0%	+159.7%	0.001%
5/19/2026	Paragon Private Wealth Management LLC	486	$0.22M	0.1%	+8.0%	0.000%
5/19/2026	Bank of America Corp DE	2,878,183	$1.29B	0.1%	-2.0%	1.134%
5/19/2026	Edgestream Partners L.P.	3,263	$1.46M	0.0%	-51.3%	0.001%
5/19/2026	Kentucky Retirement Systems	19,299	$8.62M	0.3%	+19.5%	0.008%
5/19/2026	Janus Henderson Group PLC	2,131,527	$951.80M	0.5%	-4.1%	0.840%
5/19/2026	Centaurus Financial Inc.	2,721	$1.22M	0.1%	-7.3%	0.001%
5/19/2026	Tri Locum Partners LP	129,314	$57.74M	8.1%	N/A	0.051%
5/19/2026	Oddo BHF Asset Management Sas	10,151	$4.53M	0.2%	-78.2%	0.004%
5/19/2026	Strategic Investment Advisors MI	809	$0.36M	0.0%	-46.5%	0.000%
5/19/2026	Ashton Thomas Securities LLC	3,048	$1.36M	0.2%	+5.0%	0.001%
5/19/2026	Arkadios Wealth Advisors	3,684	$1.65M	0.0%	-7.1%	0.001%
5/19/2026	Smith Group Asset Management LLC	55,746	$24.89M	1.3%	+7.1%	0.022%
5/18/2026	ADAR1 Capital Management LLC	15,075	$6.73M	0.4%	+9.9%	0.006%
5/18/2026	Amundi	1,472,496	$657.53M	0.2%	+12.9%	0.580%
5/18/2026	EverSource Wealth Advisors LLC	1,507	$0.67M	0.0%	+38.1%	0.001%
5/18/2026	California State Teachers Retirement System	373,481	$166.77M	0.2%	-3.2%	0.147%
5/18/2026	Royal Bank of Canada	1,111,871	$496.50M	0.1%	-14.1%	0.438%
5/18/2026	Empowered Funds LLC	41,737	$18.64M	0.1%	+181.9%	0.016%
5/16/2026	Ashford Capital Management Inc.	9,078	$4.05M	0.5%	+10.1%	0.004%
5/16/2026	The Manufacturers Life Insurance Company	553,243	$247.05M	0.2%	-0.8%	0.218%
5/16/2026	KCM Investment Advisors LLC	1,213	$0.54M	0.0%	+24.3%	0.000%

Data available starting January 2016

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $470.72

$468.14

$483.36

50 Day Range

MA: $471.34

$425.09

$529.59

52 Week Range

Now: $470.72

$362.50

$533.67

Volume

1,508,725 shs

Average Volume

1,462,815 shs

Market Capitalization

$119.47 billion

P/E Ratio

27.92

Dividend Yield

N/A

Beta

0.29

Who are the company insiders with the largest holdings of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top insider shareholders include:
Jeffrey M Leiden (CEO)
Joshua S Boger (Director)
Joshua Boger (Director)
Joshua S Boger (Director)
Jeffrey M Leiden (CEO)
Jeffrey Leiden (CEO)
Peter Mueller (EVP)
Ian F Smith (CFO)
Stuart A Arbuckle (EVP)
Jeffrey Chodakewitz (CMO)
Learn More about top insider investors at Vertex Pharmaceuticals.
Who are the major institutional investors of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top institutional investors include:
Assenagon Asset Management S.A. — 0.30%
Handelsbanken Fonder AB — 0.09%
Czech National Bank — 0.03%
Atwood & Palmer Inc. — 0.02%
PensionDanmark Pensionsforsikringsaktieselskab — 0.02%
Beacon Investment Advisory Services Inc. — 0.02%
Learn More about top institutional investors of Vertex Pharmaceuticals stock.
Which major investors are selling Vertex Pharmaceuticals stock?: Within the previous quarter, VRTX stock was sold by these institutional investors:
Beacon Investment Advisory Services Inc.
Handelsbanken Fonder AB
Sapient Capital LLC
LVM Capital Management Ltd. MI
Tema ETFs LLC
Dynamic Advisor Solutions LLC
BDF Gestion
MassMutual Private Wealth & Trust FSB
In the last year, company insiders that have sold Vertex Pharmaceuticals company stock include:
Amit Sachdev (EVP)
Ourania Tatsis (EVP)
Charles F Wagner Jr (EVP)
Carmen Bozic (CMO)
Jeffrey M Leiden (Chairman)
Edward Morrow Atkinson III (EVP)
Joy Liu (EVP)
Jonathan Biller (EVP)
Duncan Mckechnie (EVP)
Mark E Bunnage (EVP)
Kristen Ambrose (CAO)
Sangeeta N Bhatia (Director)
Learn More investors selling Vertex Pharmaceuticals stock.
Which major investors are buying Vertex Pharmaceuticals stock?: During the previous quarter, VRTX stock was acquired by institutional investors including:
Assenagon Asset Management S.A.
Oppenheimer Asset Management Inc.
PensionDanmark Pensionsforsikringsaktieselskab
Czech National Bank
Generali Investments Management Co LLC
RDA Financial Network
GK Wealth Management LLC
Wealth Science Advisors LLC